Journal of Neuro-Oncology

, Volume 145, Issue 3, pp 449–459 | Cite as

Analysis of CDKN2A gene alterations in recurrent and non-recurrent meningioma

  • Anne Guyot
  • Mathilde Duchesne
  • Sandrine Robert
  • Anne-Sophie Lia
  • Paco Derouault
  • Erwan Scaon
  • Leslie Lemnos
  • Henri Salle
  • Karine Durand
  • François LabrousseEmail author
Laboratory Investigation



Assessment of the risk of recurrence is essential to determine the therapeutic strategy of meningioma treatment. Many relapsing or aggressive meningiomas show elevated mitotic and/or Ki67 indices, reflecting cell cycle deregulation. As CDKN2A is a key tumor suppressor gene involved in cell cycle control, we investigated whether CDKN2A alterations may be involved in tumor recurrence.


We carried out a comparative analysis of 17 recurrent and 13 non-recurrent meningiomas. CDKN2A single nucleotide variations (SNVs), deletions, methylation status of the promotor, and p16 expression were investigated. Results were correlated with the recurrent or non-recurrent status and clinicopathological data.


We identified a CDKN2A SNV (NM_000077, exon2, c.G442A, p.Ala148Thr) in five meningiomas that was significantly associated with recurrence (p = 0.03). This mutation, confirmed by Sanger sequencing and referenced in the COSMIC database in various cancers, has not been reported in meningioma. The presence of one of the three following CDKN2A alterations—p.(Ala148Thr) mutation, whole homozygous or heterozygous gene loss, or promotor methylation > 8%—was observed in 13 of the 17 relapsing meningiomas and was strongly associated with recurrence (p < 0.0001) and a Ki67 labeling index > 7% (p = 0.004).


We report an undescribed p.(Ala148Thr) CDKN2A mutation in meningioma that was only present in relapsing tumors. In our series, CDKN2A gene alterations were only found in recurrent meningiomas. However, our results need to be evaluated on a larger series to ensure that these CDKN2A alterations can be used as biomarkers of recurrence in meningioma.


Meningioma Meningioma recurrence CDKN2A Next-generation-sequencing Methylation 



We thank the CRBiolim tumor bank collection of the Dupuytren University Hospital, and particularly Mr. Alain Chaunavel, for providing tumor and non-tumor samples and the Hight Throughput Sequencing unit of CHU Dupuytren and the Bioinformatic team of the GEIST Institute for sequencing and bioinformatic analyses. We also thank "La Ligue Contre le Cancer de la Corrèze" and the "Comité d’Organisation de la Recherche Contre le Cancer du Limousin (CORC)" whose grants allowed us to conduct this study.

Supplementary material

11060_2019_3333_MOESM1_ESM.tif (3.8 mb)
Supplementary file3 (TIFF 3913 kb)
11060_2019_3333_MOESM2_ESM.tif (11.5 mb)
Supplementary file3 (TIFF 11730 kb)
11060_2019_3333_MOESM3_ESM.docx (21 kb)
Supplementary file3 (DOCX 20 kb)


  1. 1.
    Louis DNWO, Cavenee WK (2016) WHO classification of tumours of the central nervous system. International Agency for Research on Cancer, LyonGoogle Scholar
  2. 2.
    Sahm F, Reuss DE, Giannini C (2018) WHO 2016 classification: changes and advancements in the diagnosis of miscellaneous primary CNS tumours. Neuropathol Appl Neurobiol 44:163–171. CrossRefPubMedGoogle Scholar
  3. 3.
    Yew A, Trang A, Nagasawa DT, Spasic M, Choy W, Garcia HM, Yang I (2013) Chromosomal alterations, prognostic factors, and targeted molecular therapies for malignant meningiomas. J Clin Neurosci 20:17–22. CrossRefPubMedGoogle Scholar
  4. 4.
    Saraf S, McCarthy BJ, Villano JL (2011) Update on meningiomas. Oncologist 16:1604–1613. CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Mawrin C, Perry A (2010) Pathological classification and molecular genetics of meningiomas. J Neurooncol 99:379–391. CrossRefPubMedGoogle Scholar
  6. 6.
    Burger PCSB (2007) Tumors of the central nervous system. Armed Forces Institute of Pathology, WashingtonGoogle Scholar
  7. 7.
    Voss KM, Spille DC, Sauerland C, Suero Molina E, Brokinkel C, Paulus W, Stummer W, Holling M, Jeibmann A, Brokinkel B (2017) The Simpson grading in meningioma surgery: does the tumor location influence the prognostic value? J Neurooncol 133:641–651. CrossRefPubMedGoogle Scholar
  8. 8.
    Durand A, Labrousse F, Jouvet A, Bauchet L, Kalamarides M, Menei P, Deruty R, Moreau JJ, Fevre-Montange M, Guyotat J (2009) WHO grade II and III meningiomas: a study of prognostic factors. J Neurooncol 95:367–375. CrossRefPubMedGoogle Scholar
  9. 9.
    Guillaudeau A, Durand K, Bessette B, Chaunavel A, Pommepuy I, Projetti F, Robert S, Caire F, Rabinovitch-Chable H, Labrousse F (2012) EGFR soluble isoforms and their transcripts are expressed in meningiomas. PLoS ONE 7:e37204. CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Cheng G, Zhang L, Lv W, Dong C, Wang Y, Zhang J (2015) Overexpression of cyclin D1 in meningioma is associated with malignancy grade and causes abnormalities in apoptosis, invasion and cell cycle progression. Med Oncol 32:439. CrossRefGoogle Scholar
  11. 11.
    Bostrom J, Meyer-Puttlitz B, Wolter M, Blaschke B, Weber RG, Lichter P, Ichimura K, Collins VP, Reifenberger G (2001) Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas. Am J Pathol 159:661–669. CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Ruas M, Peters G (1998) The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochem Biophys Acta 1378:F115–F177. CrossRefPubMedGoogle Scholar
  13. 13.
    Galani V, Lampri E, Varouktsi A, Alexiou G, Mitselou A, Kyritsis AP (2017) Genetic and epigenetic alterations in meningiomas. Clin Neurol Neurosurg 158:119–125. CrossRefPubMedGoogle Scholar
  14. 14.
    Alexiou GA, Markoula S, Gogou P, Kyritsis AP (2011) Genetic and molecular alterations in meningiomas. Clin Neurol Neurosurg 113:261–267. CrossRefPubMedGoogle Scholar
  15. 15.
    Lee Y, Liu J, Patel S, Cloughesy T, Lai A, Farooqi H, Seligson D, Dong J, Liau L, Becker D, Mischel P, Shams S, Nelson S (2010) Genomic landscape of meningiomas. Brain Pathol 20:751–762. CrossRefPubMedGoogle Scholar
  16. 16.
    Kim MS, Kim KH, Lee EH, Lee YM, Lee SH, Kim HD, Kim YZ (2014) Results of immunohistochemical staining for cell cycle regulators predict the recurrence of atypical meningiomas. J Neurosurg 121:1189–1200. CrossRefPubMedGoogle Scholar
  17. 17.
    Kheirollahi M, Mehr-Azin M, Kamalian N, Mehdipour P (2011) Expression of cyclin D2, P53, Rb and ATM cell cycle genes in brain tumors. Med Oncol 28:7–14. CrossRefPubMedGoogle Scholar
  18. 18.
    Derouault P, Parfait B, Moulinas R, Barrot CC, Sturtz F, Merillou S, Lia AS (2017) 'COV'COP' allows to detect CNVs responsible for inherited diseases among amplicons sequencing data. Bioinformatics 33:1586–1588. CrossRefPubMedGoogle Scholar
  19. 19.
    Ewels P, Magnusson M, Lundin S, Kaller M (2016) MultiQC: summarize analysis results for multiple tools and samples in a single report. Bioinformatics 32:3047–3048. CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Cibulskis K, McKenna A, Fennell T, Banks E, DePristo M, Getz G (2011) ContEst: estimating cross-contamination of human samples in next-generation sequencing data. Bioinformatics 27:2601–2602. CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Hirsch FR, Varella-Garcia M, Bunn PA Jr, Di Maria MV, Veve R, Bremmes RM, Baron AE, Zeng C, Franklin WA (2003) Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 21:3798–3807CrossRefGoogle Scholar
  22. 22.
    Ranade K, Hussussian CJ, Sikorski RS, Varmus HE, Goldstein AM, Tucker MA, Serrano M, Hannon GJ, Beach D, Dracopoli NC (1995) Mutations associated with familial melanoma impair p16INK4 function. Nat Genet 10:114–116. CrossRefPubMedGoogle Scholar
  23. 23.
    Walker GJ, Gabrielli BG, Castellano M, Hayward NK (1999) Functional reassessment of P16 variants using a transfection-based assay. Int J Cancer 82:305–312.;2-z CrossRefGoogle Scholar
  24. 24.
    Dal Molin M, Zhang M, de Wilde RF, Ottenhof NA, Rezaee N, Wolfgang CL, Blackford A, Vogelstein B, Kinzler KW, Papadopoulos N, Hruban RH, Maitra A, Wood LD (2015) Very long-term survival following resection for pancreatic cancer is not explained by commonly mutated genes: results of whole-exome sequencing analysis. Clin Cancer Res 21:1944–1950. CrossRefPubMedCentralGoogle Scholar
  25. 25.
    Borkowska EM, Kruk A, Jedrzejczyk A, Rozniecki M, Jablonowski Z, Traczyk M, Constantinou M, Banaszkiewicz M, Pietrusinski M, Sosnowski M, Hamdy FC, Peter S, Catto JW, Kaluzewski B (2014) Molecular subtyping of bladder cancer using Kohonen self-organizing maps. Cancer Med 3:1225–1234. CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Hirsch P, Zhang Y, Tang R, Joulin V, Boutroux H, Pronier E, Moatti H, Flandrin P, Marzac C, Bories D, Fava F, Mokrani H, Betems A, Lorre F, Favier R, Feger F, Mohty M, Douay L, Legrand O, Bilhou-Nabera C, Louache F, Delhommeau F (2016) Genetic hierarchy and temporal variegation in the clonal history of acute myeloid leukaemia. Nat Commun 7:12475. CrossRefPubMedCentralGoogle Scholar
  27. 27.
    Koulermou G, Shammas C, Vassiliou A, Kyriakides TC, Costi C, Neocleous V, Phylactou LA, Pantelidou M (2017) CDKN2A and MC1R variants found in Cypriot patients diagnosed with cutaneous melanoma. J Genet 96:155–160CrossRefGoogle Scholar
  28. 28.
    Hussussian CJ, Struewing JP, Goldstein AM, Higgins PA, Ally DS, Sheahan MD, Clark WH Jr, Tucker MA, Dracopoli NC (1994) Germline p16 mutations in familial melanoma. Nat Genet 8:15–21. CrossRefPubMedGoogle Scholar
  29. 29.
    Harland M, Meloni R, Gruis N, Pinney E, Brookes S, Spurr NK, Frischauf AM, Bataille V, Peters G, Cuzick J, Selby P, Bishop DT, Bishop JN (1997) Germline mutations of the CDKN2 gene in UK melanoma families. Hum Mol Genet 6:2061–2067. CrossRefPubMedGoogle Scholar
  30. 30.
    Dahl C, Christensen C, Jonsson G, Lorentzen A, Skjodt ML, Borg A, Pawelec G, Guldberg P (2013) Mutual exclusivity analysis of genetic and epigenetic drivers in melanoma identifies a link between p14 ARF and RARbeta signaling. Mol Cancer Res 11:1166–1178. CrossRefPubMedGoogle Scholar
  31. 31.
    Debniak T, Scott RJ, Huzarski T, Byrski T, Rozmiarek A, Debniak B, Gorski B, Cybulski C, Medrek K, Mierzejewski M, Masojc B, Matyjasik J, Zlowocka E, Teodorczyk U, Lener M, Klujszo-Grabowska E, Nej-Wolosiak K, Jaworowska E, Oszutowska D, Szymanska A, Szymanska J, Castaneda J, van de Wetering T, Suchy J, Kurzawski G, Oszurek O, Narod S, Lubinski J (2006) CDKN2A common variant and multi-organ cancer risk—a population-based study. Int J Cancer 118:3180–3182. CrossRefPubMedGoogle Scholar
  32. 32.
    Dong Y, Wang X, Yang YW, Liu YJ (2017) The effects of CDKN2A rs3731249, rs11515, and rs3088440 polymorphisms on cancer risk. Cell Mol Biol 63:40–44. CrossRefGoogle Scholar
  33. 33.
    Bakos RM, Besch R, Zoratto GG, Godinho JM, Mazzotti NG, Ruzicka T, Bakos L, Santos SE, Ashton-Prolla P, Berking C, Giugliani R (2011) The CDKN2A p. A148T variant is associated with cutaneous melanoma in Southern Brazil. Exp Dermatol 20:890–893. CrossRefGoogle Scholar
  34. 34.
    Spica T, Portela M, Gerard B, Formicone F, Descamps V, Crickx B, Ollivaud L, Archimbaud A, Dupin N, Wolkenstein P, Vitoux D, Lebbe C, Saiag P, Basset-Seguin N, Fargnoli MC, Grandchamp B, Peris K, Soufir N, Melan C (2006) The A148T variant of the CDKN2A gene is not associated with melanoma risk in the French and Italian populations. J Invest Dermatol 126:1657–1660. CrossRefPubMedGoogle Scholar
  35. 35.
    Peyre M, Salaud C, Clermont-Taranchon E, Niwa-Kawakita M, Goutagny S, Mawrin C, Giovannini M, Kalamarides M (2015) PDGF activation in PGDS-positive arachnoid cells induces meningioma formation in mice promoting tumor progression in combination with Nf2 and Cdkn2ab loss. Oncotarget 6:32713–32722. CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Bello MJ, Aminoso C, Lopez-Marin I, Arjona D, Gonzalez-Gomez P, Alonso ME, Lomas J, de Campos JM, Kusak ME, Vaquero J, Isla A, Gutierrez M, Sarasa JL, Rey JA (2004) DNA methylation of multiple promoter-associated CpG islands in meningiomas: relationship with the allelic status at 1p and 22q. Acta Neuropathol 108:413–421. CrossRefPubMedGoogle Scholar
  37. 37.
    Amatya VJ, Takeshima Y, Inai K (2004) Methylation of p14(ARF) gene in meningiomas and its correlation to the p53 expression and mutation. Mod Pathol 17:705–710. CrossRefPubMedGoogle Scholar
  38. 38.
    Sahm F, Schrimpf D, Stichel D, Jones DTW, Hielscher T, Schefzyk S, Okonechnikov K, Koelsche C, Reuss DE, Capper D, Sturm D, Wirsching HG, Berghoff AS, Baumgarten P, Kratz A, Huang K, Wefers AK, Hovestadt V, Sill M, Ellis HP, Kurian KM, Okuducu AF, Jungk C, Drueschler K, Schick M, Bewerunge-Hudler M, Mawrin C, Seiz-Rosenhagen M, Ketter R, Simon M, Westphal M, Lamszus K, Becker A, Koch A, Schittenhelm J, Rushing EJ, Collins VP, Brehmer S, Chavez L, Platten M, Hanggi D, Unterberg A, Paulus W, Wick W, Pfister SM, Mittelbronn M, Preusser M, Herold-Mende C, Weller M, von Deimling A (2017) DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. Lancet Oncol 18:682–694. CrossRefPubMedGoogle Scholar
  39. 39.
    Jiao Y, Feng Y, Wang X (2018) Regulation of tumor suppressor gene CDKN2A and encoded p16-INK4a protein by covalent modifications. Biochemistry (Mosc) 83:1289–1298. CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Anne Guyot
    • 1
  • Mathilde Duchesne
    • 1
  • Sandrine Robert
    • 2
  • Anne-Sophie Lia
    • 3
  • Paco Derouault
    • 3
  • Erwan Scaon
    • 4
  • Leslie Lemnos
    • 5
  • Henri Salle
    • 5
  • Karine Durand
    • 1
    • 2
  • François Labrousse
    • 1
    • 2
    Email author
  1. 1.Department of PathologyLimoges University HospitalLimogesFrance
  2. 2.EA 3842, CAPTuR « Contrôle de L’Activation Cellulaire, Progression Tumorale Et Résistance Thérapeutique », Faculty of MedicineLimoges UniversityLimogesFrance
  3. 3.EA 6309, MMNP « Maintenance Myélinique Et Neuropathies Périphériques », Faculty of MedicineLimoges UniversityLimogesFrance
  4. 4.Bioinformatics Unit, BISCEM Platform, CBRSUniversity of LimogesLimogesFrance
  5. 5.Department of NeurosurgeryLimoges University HospitalLimogesFrance

Personalised recommendations